Scroll for Important Safety Information and Indications

INDICATIONS

Prevnar 13^® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)

Limitations of Use and Effectiveness

Prevnar 13^® will only help protect against S. pneumoniae serotypes in the vaccine

IMPORTANT SAFETY INFORMATION AND INDICATIONS

Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13^® or any diphtheria toxoid–containing vaccine is a contraindication
Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks
In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
In children 6 years through 17 years of age, Prevnar 13^® is administered as a single dose

INDICATIONS

Prevnar 13^® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)

Limitations of Use and Effectiveness

Prevnar 13^® will only help protect against S. pneumoniae serotypes in the vaccine

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for Prevnar 13^®.

Reference:

1.Prevnar 13^® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) Prescribing Information, Wyeth Pharmaceuticals, Inc, 2016.

Resources

Dr. Scott Video

Watch Dr. Scott as she shares her personal story about how IPD took her infant's life.

Vaccines are not 100% effective, and Prevnar 13^® will only help protect against serotypes in the vaccine. Help protect your patients with all 4 doses of the Prevnar 13^® vaccine.

Office Materials Available From Your Pfizer Representative

Contact your Pfizer Representative to request educational materials about Prevnar 13^®.

Useful Websites

BabyVaxFacts
www.babyvaxfacts.com

The following websites are neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of these sites.

American Academy of Pediatrics
www.aap.org

American Academy of Family Physicians
www.aafp.org

American Nurses Association
www.nursingworld.org

Association for Early Learning Leaders
www.earlylearningleaders.org

Every Child By Two
www.ecbt.org

The History of Vaccines
www.historyofvaccines.org

Immunization Action Coalition
www.immunize.org